We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 32 for:    Not yet recruiting Studies | bipolar

Bipolar Transcranial Alternating Current Stimulation (tACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05480124
Recruitment Status : Not yet recruiting
First Posted : July 29, 2022
Last Update Posted : January 19, 2023
Sponsor:
Collaborators:
Milken Institute
Baszucki Brain Research Fund
Information provided by (Responsible Party):
Stephan F. Taylor, University of Michigan

Brief Summary:

The purpose of this clinical trial is to measure the safety and effectiveness of a non-invasive brain stimulation device called Transcranial Alternating Current Stimulation (tACS) in participants with bipolar disorder (BD).

Participants will be asked to come in for 3 sessions. If participants qualify at the screening visit (session 1) then enrolled participants will complete sessions 2 and 3 as well as have a 30-day follow-up phone call.


Condition or disease Intervention/treatment Phase
Bipolar Disorder Device: tACS brain stimulation treatment Device: Sham stimulation treatment Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Participants, study coordinator, and clinical assessor will be blind as to which session the participants receive active or sham treatment.
Primary Purpose: Treatment
Official Title: Enhancing Neural Synchrony and Affective Cognitive Control in Bipolar Disorder Using Personalized Transcranial Alternating Current Stimulation (tACS)
Estimated Study Start Date : February 2023
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2023


Arm Intervention/treatment
Sham Comparator: Sham stimulation treatment
Sham stimulation during a computerized task and electroencephalogram (EEG) recording.
Device: Sham stimulation treatment
Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.

Experimental: tACS brain stimulation treatment
tACS brain stimulation during a computerized task and EEG recording. Participants will receive tACS using individualized peak Phase-amplitude coupling (PAC) frequency pairs determined in Session 1.
Device: tACS brain stimulation treatment
Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.




Primary Outcome Measures :
  1. Severity of side effects reported at end of stimulation session as reported by the participant on the Stimulation Side Effects Questionnaire. [ Time Frame: Change in outcome between Session 2 (approximately 60 minutes) and session 3 (approximately 60 minutes) ]
    The score is calculated by summing the severity score of items (0-4) that are rated by the participant as related to stimulation (ratings of 3=probable or 4=definite) on the Stimulation Side Effects Questionnaire. There are a total of 14 symptoms as well as an other category with scores ranging from 0-56 and the possibility of more points if other symptoms are recorded.

  2. Percentage of participants that withdrawal during or after the stimulation session [ Time Frame: Change in outcome between Session 2 (approximately 60 minutes) and session 3 (approximately 60 minutes) ]
    The study team will compare the percentage of participants requesting to discontinue the session and the severity of side effects reported following the tACS vs. sham procedure.

  3. Accuracy signal detection theory metric sensitivity (d') derived from the behavioral responses to Go and NoGo trials on the cognitive control task. [ Time Frame: Change in outcome between Session 2 (approximately 60 minutes) and session 3 (approximately 60 minutes) ]
    D' (D prime) provides a measure of perceptual sensitivity to differing stimuli.

  4. Accuracy signal detection theory metric response bias derived from the behavioral responses to Go and NoGo trials on the cognitive control task. [ Time Frame: Change in outcome between Session 2 (approximately 60 minutes) and 3 (approximately 60 minutes) ]
    Beta (β) provides a measure of response bias, with negative β values indicating a stronger tendency to respond.

  5. Reaction time (in milliseconds) of Go trials on the cognitive control task [ Time Frame: Change in outcome between Session 2 (approximately 60 minutes) and 3 (approximately 60 minutes) ]
    The separate sessions will be measured separately and compared to each other.

  6. Theta-gamma PAC (Kullback-Leibler Modulation Index) during the rest EEG blocks interleaved between stimulation blocks. [ Time Frame: Change in outcome between Session 2 (approximately 60 minutes) and 3 (approximately 60 minutes) ]
    Theta-Gamma PAC represents the relationship between the phase of theta oscillations and the amplitude of gamma oscillations as measured by the EEG.


Other Outcome Measures:
  1. Emotional Flanker Task - Accuracy [ Time Frame: Approximately 30-60 minutes after the Go-NoGo task at all three time points (baseline, session 1, session 2) ]
    After completing the Emotion Go-NoGo task, participants will complete another cognitive control task (i.e., Emotional Flanker Task) with gray-scaled unpleasant, pleasant, and neural images from the International Affective Picture System. Participants are tasked with indicating which valance is presented in certain images while ignoring other images. Accuracy is defined as the percentage of trials that the participant correctly reports the valance of the target image. The total number of correct trials will be divided by the total number of trials to obtain an accuracy score. Average accuracy scores per condition and total will be calculated.

  2. Emotional Flanker Task - Reaction time [ Time Frame: Approximately 30-60 minutes after the Go-NoGo task at all three time points (baseline, session 1, session 2). ]
    Reaction time will also be collected during the Emotional Flanker Task. Reaction time is defined as the length of time it takes the participant to respond after the onset of the stimuli. Average reaction times per condition and total will be calculated.

  3. Emotional Flanker Task - EEG [ Time Frame: Approximately 30-60 minutes after the Go-NoGo task at all three time points (baseline, session 1, session 2). ]
    EEG will also be collected during the Emotional Flanker Task. Phase-amplitude coupling will be calculated and defined as the coupling between the amplitude of high frequency oscillations (e.g., gamma) and low frequency phase (e.g., theta). Average coupling scores per condition and total will be calculated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed diagnosis of BD based on Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria being met from previous enrollment in the Prechter Bipolar Longitudinal Study
  • This study will select BD patients that scored 1.5 standard deviations (SDs) above published norms on the total score of the Barratt Impulsiveness Scale to ensure that the recruited patients exhibit the network dysfunction targeted by the tACS paradigm and therefore have the potential to benefit from this neuromodulation technique.
  • Patients must be on a stable dose of medication for two weeks prior to Sessions 2 and 3.

Exclusion Criteria:

  • Significant neurological abnormalities, such as seizure disorder, mass lesions, etc.
  • Known Mendelian disorder
  • Active problematic substance use in the past 30 days (as determined by the Substance Use Disorder module of SCID)
  • Evidence of suicidal intentions or behaviors in the past month, as judged by affirmative responses to question number 4 or number 5 on the Columbia Suicide Severity Rating Scale (CSSRS) or report of suicidal behaviors in the last 6 months
  • Pregnant or trying to become pregnant, or currently lactating.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05480124


Contacts
Layout table for location contacts
Contact: Laura Locarno 734-232-4585 tacs_study@med.umich.edu

Locations
Layout table for location information
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Contact: Laura Stchur, MSW    734-936-1323    lmarine@med.umich.edu   
Principal Investigator: Ivy Tso, PhD         
Sponsors and Collaborators
University of Michigan
Milken Institute
Baszucki Brain Research Fund
Investigators
Layout table for investigator information
Principal Investigator: Stephan F Taylor, MD University of Michigan
Layout table for additonal information
Responsible Party: Stephan F. Taylor, Professor of Psychiatry, University of Michigan
ClinicalTrials.gov Identifier: NCT05480124    
Other Study ID Numbers: HUM00208557
First Posted: July 29, 2022    Key Record Dates
Last Update Posted: January 19, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Stephan F. Taylor, University of Michigan:
transcranial alternating current stimulation (tACS)
electroencephalogram (EEG)
Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Bipolar and Related Disorders
Mental Disorders